Thus, it could be hypothesized that treatment with anti-PD-L1 or anti-PD-1 immunotherapy could be a promising future treatment in patients with IPF and mPD-L1 expression. This evidence concerns the gene CD274 and idiopathic pulmonary fibrosis.